Clinical trial
Study Evaluation Tazocin Intervention
NCT00488189 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00488189 |
|---|---|
| Title | Study Evaluation Tazocin Intervention |
| Official title | Association of Antibiotic Utilization Measures and Control of Extended-Spectrum β-Lactamases (ESBLs) Producing Bacteria |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Bacterial Infections |
| Intervention type | Drug |
| Interventions | Tazocin (pipercillin/tazobactam) |
| Enrollment | 134 |
| Start date | May 1, 2007 |
| Primary completion | Feb 1, 2008 |
| Completion | Feb 1, 2008 |
| First posted | Jun 20, 2007 |
| Last update posted | Apr 15, 2011 |
| Countries | China |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: